The survey also showed that many believe value-based care is being gamed and that chances that it will be successful are small.
Weaning U.S. healthcare off fee-for-service payment to value-based care arrangements that reward cost-effective care has been talked about for years. But walking that talk has been a halting, sort of effort for a tangled set of reasons, not the least of which is the ingrained, staying power of fee for service
The Managed Healthcare Executive® State of the Industry confirmed that the move toward valued-based has been modest and revealed some jaded views.
Asked to rate their own organization’s shift away from fee for service to value-based care, 12% of the 450 respondents indicated they hadn’t started, 27% indicated beginning and 27% indicated midway. Only 17% rated their organization as being mainly in value-based arrangements.
About one-third (34%) of the respondents indicated agreement with the statement that value-based care arrangements and payment models are “admirable but the chances of success are small.” A large proportion (41%) agree with the statement that they have been “gamed by some organizations to increase profits and revenues.”
There is some optimism, albeit tethered. A large if minority group of the respondents (37%) said the value-based arrangements were on the right track but needed adjustment. Abou the same proportion (39%) said the arrangements don’t provide enough of an incentive to lower healthcare spending.
Accountable care organizations (ACOs) and bundled or episodic payment arrangements have gotten a great deal of attention. But 39% of the respondents to the survey said pay-for-performance incentives were most likely to be successful in improving outcomes and reducing costs this year. Only 20% thought ACOs would and only 18% thought bundled payments would.
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Conversations with Perry and Friends: Saar Mahna, J.D., MBA
July 7th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the "Conversations with Perry and Friends" podcast. In this episode, Cohen speaks with Saar Mahna, J.D., MBA, CEO and founder of Banjo Health, an artificial intelligence company focused on prior authorization.
Listen
PBM-Offered Genomics Testing Could Reshape Prescribing of Medications
July 25th 2025Two PBMs, True Rx Health Strategies and Capital Rx, are using pharmacogenomics — how a person’s DNA affects their response to medications — to reduce the trial-and-error of prescribing medications, saving employers and patients time and money.
Read More
Conversations With Perry and Friends: Paul Fronstin, Ph.D.
May 9th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. In this episode, his guest is Paul Fronstin, Ph.D., director of health benefits research at the Employee Benefit Research Institute.
Listen
FDA Accepts Tabelecleucel BLA; Priority Review Granted for Post-Transplant Disease Therapy
July 24th 2025The FDA has accepted the resubmitted BLA for tabelecleucel (tab-cel), intended for the treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD).
Read More